These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33245861)

  • 21. To achieve "zero covid" we need to include the controlled, careful acquisition of population (herd) immunity.
    Bhopal RS
    BMJ; 2020 Sep; 370():m3487. PubMed ID: 32907816
    [No Abstract]   [Full Text] [Related]  

  • 22. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.
    Kwok KO; Lai F; Wei WI; Wong SYS; Tang JWT
    J Infect; 2020 Jun; 80(6):e32-e33. PubMed ID: 32209383
    [No Abstract]   [Full Text] [Related]  

  • 24. Herd immunity and a vaccination game: An experimental study.
    Lim W; Zhang P
    PLoS One; 2020; 15(5):e0232652. PubMed ID: 32407329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
    Anderson RM; Vegvari C; Truscott J; Collyer BS
    Lancet; 2020 Nov; 396(10263):1614-1616. PubMed ID: 33159850
    [No Abstract]   [Full Text] [Related]  

  • 26. Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?
    Laxminarayan R; John TJ
    Indian Pediatr; 2020 Jun; 57(6):505-507. PubMed ID: 32376793
    [No Abstract]   [Full Text] [Related]  

  • 27. Our choice is not binary between lockdown and herd immunity.
    Cheng KK
    BMJ; 2020 Oct; 371():m4051. PubMed ID: 33093027
    [No Abstract]   [Full Text] [Related]  

  • 28. Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan.
    Takita M; Matsumura T; Yamamoto K; Yamashita E; Hosoda K; Hamaki T; Kusumi E
    QJM; 2020 Nov; 113(11):785-786. PubMed ID: 32467977
    [No Abstract]   [Full Text] [Related]  

  • 29. Four months into the COVID-19 pandemic, Sweden's prized
    Orlowski EJW; Goldsmith DJA
    J R Soc Med; 2020 Aug; 113(8):292-298. PubMed ID: 32780968
    [No Abstract]   [Full Text] [Related]  

  • 30. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão.
    Silva AAMD; Lima-Neto LG; Azevedo CMPES; Costa LMMD; Bragança MLBM; Barros Filho AKD; Wittlin BB; Souza BF; Oliveira BLCA; Carvalho CA; Thomaz EBAF; Simões-Neto EA; Leite Júnior JF; Cosme LMSS; Campos MAG; Queiroz RCS; Costa SS; Carvalho VA; Simões VMF; Alves MTSSBE; Santos AMD
    Rev Saude Publica; 2020; 54():131. PubMed ID: 33331525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.
    Britton T; Ball F; Trapman P
    Science; 2020 Aug; 369(6505):846-849. PubMed ID: 32576668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in adaptation of fifteen European countries population to SARS-CoV-2 in March-May 2020: Can Taiwanese experience be adopted?
    Sharov KS
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):679-687. PubMed ID: 32798031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.
    Shelly A; Gupta P; Ahuja R; Srichandan S; Meena J; Majumdar T
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33050511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the relationship between BCG coverage and national COVID-19 outcome: could 'heterologous' herd immunity explain why some countries are better off?
    Lerm M
    J Intern Med; 2020 Dec; 288(6):682-688. PubMed ID: 33107999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Leaving' resilience for the future? Exploring the difficulty of achieving herd immunity against COVID-19 in the Philippines.
    Cordero DA
    J Public Health (Oxf); 2022 Dec; 44(4):e652-e653. PubMed ID: 36455611
    [No Abstract]   [Full Text] [Related]  

  • 36. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.
    Yoo JH
    J Korean Med Sci; 2021 Feb; 36(6):e54. PubMed ID: 33559409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current status of COVID-19 pandemic and progress in response strategy].
    Gao WJ; Wang B; Lyu J; Yu CQ; Wang L; Li LM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jan; 42(1):22-27. PubMed ID: 33197990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunity against SARS-CoV-2: walking to the vaccination].
    Rodríguez Hernández C; Sanz Moreno L
    Rev Esp Quimioter; 2020 Dec; 33(6):392-398. PubMed ID: 32935536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential alteration of COVID-19 by beta-mercaptoethanol.
    Click RE
    Future Microbiol; 2020 Sep; 15():1313-1318. PubMed ID: 32951474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.